Lilly, known for injectable drugs like Zepbound for obesity and Mounjaro and Trulicity for diabetes, is among several ...

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary endpoint of superior A1C reduction vs. placebo at 40 weeks.

Stocks ended in the red for the holiday-shortened week, as developments over tariffs and tensions between U.S. President Donald Trump and Federal Reserve chair Jerome Powell continued to dominate ...

A new GLP-1 drug, orforglipron, comes in pill form and appears to be roughly as effective as injected drugs like Ozempic.

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...